远程心电监测筛查心房颤动:REHEARSE-AF研究
REHEARSE-AF随机对照试验纳入1001例≥65岁、CHADS-VASc≥2且无心房颤动的门诊患者,比较每周两次单导联iECG远程判读筛查与常规护理。卒中/短暂性脑缺血发作/系统性栓塞事件两组相似(6 vs 10,HR 0.61,95%CI 0.22-1.69,P=0.34)。
要点
- ≥65岁、CHADS-VASc≥2患者每周两次iECG筛查可提高心房颤动检出(HR 3.9)。
- 筛查未显著减少卒中/短暂性脑缺血发作/系统性栓塞事件(P=0.34)。
核心结论
- 在≥65岁、CHADS-VASc≥2的门诊患者中,每周两次单导联iECG远程判读筛查较常规护理显著提高12个月内心房颤动检出率。
研究设计与样本
- 随机对照试验纳入1001例无心房颤动的门诊患者(iECG组500例,常规护理组501例),平均年龄72.6±5.4岁,女性534例,平均CHADS-VASc评分3.0。
- iECG组在12个月内每周采集两次iECG(有症状时额外采集),经自动心房颤动检测算法及心脏生理学家和/或顾问心内科医生判读。
主要发现
- 卒中/短暂性脑缺血发作/系统性栓塞事件iECG组6例,常规护理组10例(HR 0.61,95%CI 0.22-1.69,P=0.34)。
- 多数iECG患者对设备满意,认为易于使用且不限制活动或引起焦虑。
临床怎么用
- 对≥65岁、CHADS-VASc≥2且无心房颤动的门诊患者,可考虑每周两次单导联iECG远程判读筛查以提高心房颤动检出。
- 该筛查策略在本研究中未显著减少卒中/短暂性脑缺血发作/系统性栓塞事件,需更大规模事件驱动试验进一步评估。
局限性
- 研究未设盲法,主要终点为心房颤动诊断时间,临床事件为次要观察。
- 卒中/短暂性脑缺血发作/系统性栓塞事件数较少,置信区间宽,不足以评估对硬终点的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asymptomatic atrial fibrillation (AF) is increasingly common in the aging population and implicated in many ischemic strokes. Earlier identification of AF with appropriate anticoagulation may decrease stroke morbidity and mortality. METHODS: We conducted a randomized controlled trial of AF screening using an AliveCor Kardia monitor attached to a WiFi-enabled iPod to obtain ECGs (iECGs) in ambulatory patients. Patients ≥65 years of age with a CHADS-VASc score ≥2 free from AF were randomized to the iECG arm or routine care (RC). iECG participants acquired iECGs twice weekly over 12 months (plus additional iECGs if symptomatic) onto a secure study server with overread by an automated AF detection algorithm and by a cardiac physiologist and/or consultant cardiologist. Time to diagnosis of AF was the primary outcome measure. The overall cost of the devices, ECG interpretation, and patient management were captured and used to generate the cost per AF diagnosis in iECG patients. Clinical events and patient attitudes/experience were also evaluated. RESULTS: We studied 1001 patients (500 iECG, 501 RC) who were 72.6±5.4 years of age; 534 were female. Mean CHADS-VASc score was 3.0 (heart failure, 1.4%; hypertension, 54%; diabetes mellitus, 30%; prior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%; all CHADS-VASc risk factors were evenly distributed between groups). Nineteen patients in the iECG group were diagnosed with AF over the 12-month study period versus 5 in the RC arm (hazard ratio, 3.9; 95% confidence interval=1.4-10.4; P=0.007) at a cost per AF diagnosis of $10 780 (£8255). There was a similar number of stroke/transient ischemic attack/systemic embolic events (6 versus 10, iECG versus RC; hazard ratio=0.61; 95% confidence interval=0.22-1.69; P=0.34). The majority of iECG patients were satisfied with the device, finding it easy to use without restricting activities or causing anxiety. CONCLUSIONS: Screening with twice-weekly single-lead iECG with remote interpretation in ambulatory patients ≥65 years of age at increased risk of stroke is significantly more likely to identify incident AF than RC over a 12-month period. This approach is also highly acceptable to this group of patients, supporting further evaluation in an appropriately powered, event-driven clinical trial. CLINICAL TRIAL REGISTRATION: URL: https://www.isrctn.com. Unique identifier: ISRCTN10709813.
引用
- Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation. 2017. PMID: 28851729. doi:10.1161/CIRCULATIONAHA.117.030583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。